pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Windward Bio AG

updated 3mo ago
Website ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 1: 1
1Phase 1
Phase 1
QX-027N
Chronic Obstructive Pulmonary Disease (COPD)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Windward Bio AG jobs →

News

  • Windward Bio hits Nasdaq with $175M IPO, plus another $50M from Sanofi
    Windward Bio, a biotech developing drugs for respiratory diseases, made its public debut after putting together $175 million in its IPO. The company began trading Friday with an initial share price…
    endpoints · 3d ago
  • Windward nets $175M IPO, bringing 2026 biotech debuts to 35
    Windward Bio’s public debut brings this year’s IPO count well above the sluggish total of eight in 2025.
    biospace · 3d ago
  • Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
    Windward Bio’s IPO has blown to exactly the spot the Swiss biotech had been aiming for, bringing in $225 million to fund a pair of respiratory drugs licensed from China.
    fiercebiotech · 4d ago
  • Windward prices $175M IPO to advance China-licensed lung drugs
    The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
    biopharma_dive · 4d ago
  • Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
    Windward Bio is sailing toward the public markets with the aim of raising over $200 million in proceeds to fund two respiratory drugs licensed from China.
    fiercebiotech · 8d ago
  • Lycia leaps onto Nasdaq with upsized $318M IPO as Windward breezes toward listing
    Lycia Therapeutics went public with an upsized $317.5 million IPO on Friday, while immunology-focused Windward Bio is hoping to catch the same tailwinds.
    fiercebiotech · 22d ago
  • Windward Bio files for Nasdaq IPO to fund China-derived assets and in-house R&D
    A 2-year-old European biotech with two clinical-stage assets from China is the latest to attempt an initial public offering in the US. Basel-based Windward Bio submitted its cards for a Nasdaq ...
    endpoints · 24d ago
  • Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12
    Plus news about Structure Therapeutics, Cloverleaf Bio and Windward Bio. FDA finalizes Krazati withdrawal: Regulators officially finalized the drug’s withdrawal in second-line colorectal cancer las…
    endpoints · 2mo ago
  • Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial
    A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised a ...
    endpoints · 6mo ago
view all news mentions →
identifiers
source
globaldata
top tags
Dermatology1Pulmonology1
mentioned in
9news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?